After an almost four-decade hiatus, the study of mind-altering substances, including MDMA (ecstasy), ketamine, psilocybin (mushrooms) and LSD is starting to resume in full force. Over the past decade, the Multidisciplinary Association for Psychedelic Research (MAPS) has sponsored groundbreaking studies, including in MDMA-assisted therapy for PTSD, and for end-of-life anxiety. Mind altering substances have the potential to profoundly alter perceptions of one’s relationship to past experience, as well as visions of the future, and to promote self-compassion and self-acceptance. Therefore, psychedelic assisted therapy may be particularly effective for dealing with post-traumatic states of being emotionally stuck, frozen, rigid, terrified and ashamed. This workshop will focus in how we can best document and characterize both the short term and long-term alterations in self-perception, sense of belonging, agency, self-compassion and capacity for intimacy, and how we can delineate the differential effects of various substances. We will present a wealth of case histories, as well as cutting edge scientific data about the outcome and process of mind-altering substances on mental, interpersonal and biological dimensions.
- Discuss the emerging research of MDMA-Assisted Psychotherapy (MDMA-AP) and describe effective ways of integrating it into ongoing psychotherapy to improve clinical outcomes for clients with PTSD.
- Examine and describe the history and contemporary research of Psilocybin and evaluate the effectiveness of Psilocybin-Assisted Psychotherapy (PAP) in facilitating psychotherapy.
- Describe and communicate the ongoing work with Ketamine-Assisted Psychotherapy (KAP) and synthesize methods of integration of psychedelic-assisted therapy in contemporary treatment for mental illness.